共 50 条
- [21] Early safety assessment of durvalumab after sCRT in patients with stage III, unresectable NSCLC (PACIFIC-6)JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S737 - S737Garassino, M. C.Mazieres, J.Reck, M.Delmonte, A.Bischoff, H. G.Bernabe, R.Perez, I. DiazSawyer, W.Trunova, N.Faivre-Finn, C.
- [22] Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian CohortJOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S282 - S283Gibson, A.Dean, M.Elegbede, A.Pabani, A.Bebb, G.Cheung, W.
- [23] PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)ANNALS OF ONCOLOGY, 2024, 35 : S1624 - S1624Wu, Y-L.Wu, L.Bi, N.Cil, T.Ge, H.Zhu, Z.Wang, C-L.Zhang, W.Lv, D.Sun, J.Pan, Y.Krzakowski, M.Dikilitas, M.Sendur, M. A. N.Kim, Y-C.Yang, Y.Mao, R.Zhang, B.Wang, L.
- [24] Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLCJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 868 - 872Hellyer, Jessica A.Aredo, Jacqueline, VDas, MillieRamchandran, KavithaPadda, Sukhmani K.Neal, Joel W.Wakelee, Heather A.
- [25] DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapyFUTURE ONCOLOGY, 2021, 17 (34) : 4657 - 4663Filippi, Andrea R.Dziadziuszko, RafalGarcia Campelo, Maria RosarioPaoli, Jean-BaptisteSawyer, WilliamDiaz Perez, Ignacio Esteban
- [26] Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R StudyJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : e38 - e39Zhao, BinghaoLi, HuanzhangMa, Wenbin
- [27] Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLCJOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (02): : 153 - +Mehra, RaneeYong, CandiceSeal, Brianvan Keep, MarjolijnRaad, AngieZhang, Yiduo
- [28] Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLCJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1044 - S1044Huang, Y.Zhao, J.Soon, Y. Y.Wong, A.Ang, Y.Asokumaran, Y.Low, J. L.Lee, M.Choo, J.Chan, G.Kee, A.Tay, S. H.Goh, B. C.Soo, R.
- [29] Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancerTHORACIC CANCER, 2020, 11 (06) : 1541 - 1549Chu Chia-HsunChiu Tzu-HsuanWang Chin-ChouChang Wen-ChenHuang Allen Chung-ChengLiu Chien-YingWang Chih-LiangKo Ho-WenChung Fu-TsaiHsu Ping-ChihGuo Yi-KeKuo, Chih-Hsi S.Yang Cheng-Ta
- [30] Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyJOURNAL OF THORACIC ONCOLOGY, 2024, 19 (06) : 928 - 940Nassar, Amin H.Kim, So YeonAredo, Jacqueline, VFeng, JamieShepherd, FrancesXu, ChaoKaldas, DavidGray, Jhanelle E.Dilling, Thomas J.Neal, Joel W.Wakelee, Heather A.Liu, YufeiLin, Steven H.Abuali, TariqAmini, AryaNie, YunanPatil, TejasLobachov, AnastasiyaBar, JairFitzgerald, BaileyFujiwara, YuMarron, Thomas U.Thummalapalli, RohitYu, HelenaOwen, Dwight H.Sharp, JohnFarid, SairaRocha, PedroArriola, Edurne'Aiello, AngelicaCheng, HaiyingWhitaker, RyanParikh, KaushalAshara, YashChen, LuxiSankar, KamyaHarris, Jeremy P.Nagasaka, MisakoAyanambakkam, AdanmaVelazquez, Ana I.Ragavan, MeeraLin, Jessica J.Piotrowska, Zo fiaWilgucki, MollyReuss, JoshuaLuders, HeikeGrohe, ChristianEspinar, Javier BaenaFeiner, EllaPunekar, Salman R.